Loading...
XSTODMYD B
Market cap150mUSD
Dec 23, Last price  
16.54SEK
1D
3.63%
1Q
20.73%
Jan 2017
186.95%
IPO
541.09%
Name

Diamyd Medical AB

Chart & Performance

D1W1MN
XSTO:DMYD B chart
P/E
—
P/S
12,863.03
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.18%
Rev. gr., 5y
-39.23%
Revenues
130k
-76.19%
113,028,000280,752,0001,078,000100,000443,000513,000757,000922,000726,0001,568,000341,000253,000454,000546,000130,000
Net income
-152m
L+30.82%
-332,000102,570,000-51,675,000-12,633,000-16,034,000-21,397,000-32,008,000-25,555,000-43,953,000-36,731,0009,709,000204,007,000-88,857,000-116,073,000-151,850,000
CFO
-129m
L+16.42%
225,774,000-94,027,000-55,987,000-13,715,000-16,690,000-18,311,000-17,752,000-25,808,000-41,564,000-39,185,00016,880,000-109,468,000-93,219,000-110,962,000-129,181,000

Profile

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
URL
https://www.diamyd.com/
IPO date
May 20, 2013
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑082015‑08
Income
Revenues
130
-76.19%
546
20.26%
454
79.45%
Cost of revenue
100,194
73,543
91,639
Unusual Expense (Income)
NOPBT
(100,064)
(72,997)
(91,185)
NOPBT Margin
Operating Taxes
4,734
(14,659)
Tax Rate
NOPAT
(100,064)
(77,731)
(76,526)
Net income
(151,850)
30.82%
(116,073)
30.63%
(88,857)
-143.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
135,208
75,271
150,000
BB yield
-8.69%
-9.82%
-13.13%
Debt
Debt current
(57)
Long-term debt
30,672
15,865
Deferred revenue
Other long-term liabilities
421
692
778
Net debt
(109,597)
(122,809)
(135,281)
Cash flow
Cash from operating activities
(129,181)
(110,962)
(93,219)
CAPEX
(8,025)
(11,442)
(34,652)
Cash from investing activities
(27,994)
28,401
(76,722)
Cash from financing activities
142,284
86,542
142,155
FCF
(97,099)
(84,304)
(104,526)
Balance
Cash
132,366
127,533
159,668
Long term investments
7,903
11,141
(24,444)
Excess cash
140,262
138,647
135,201
Stockholders' equity
(440,429)
(290,889)
(176,128)
Invested Capital
617,442
476,843
391,228
ROIC
ROCE
EV
Common stock shares outstanding
94,713
78,286
78,385
Price
16.42
67.72%
9.79
-32.85%
14.58
-56.74%
Market cap
1,555,181
102.92%
766,416
-32.94%
1,142,847
-53.74%
EV
1,445,584
643,607
1,007,566
EBITDA
(94,484)
(68,128)
(86,802)
EV/EBITDA
Interest
2,140
3
253
Interest/NOPBT